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Reply 
To the Editors: 
Thank you for giving us the opportunity to respond to 
Dr. Sandmann's letter. We thank him for his detailed 
critique of our article. Such discussion is to be encouraged 
when new methods of treatment are introduced, and 
especially when those new methods are as revolutionary as
the endoluminal method ofaneurysm repair. We agree with 
Dr. Sandmann that the long-term outcome of the endolu- 
minal method are unknown. The medium-term outcome, 
however, is known. We have used the endoluminal method 
to treat abdominal ortic aneurysms in 106 patients, and we 
reported 32 of these who had their operation 2 years ago or 
more. ~ In addition, we have reported 47 patients who had 
their aneurysms repaired with the endoluminal method 1 
year ago or more who were followed-up at 6-month 
intervals with contrast-enhanced computed tomographic 
scans. 2 The durability of the repair and the observed 
diminution in size of the aneurysm in these studies have 
encouraged us to continue with the method. 
We also agree that close follow-up is mandatory after 
endoluminal bdominal ortic aneurysm repair. The patient 
who is the subject of the report is able to return for regular 
elective reviews but does not have access to emergency 
vascular surgical care. We were not as confident as Dr. 
Sandmann that dissection of the descending thoracic aorta 
was benign and stable, particularly with respect o the 
possibility of late complications developing if the entry 
point was not closed. 
To clarify some other points raised in Dr. Sandmann's 
letter, we can confirm that the patient was normotensive, 
with normal renal arteries demonstrated on aortographic 
scans. The images that were published were selected to 
demonstrate he dissection and were not the best in the 
series to demonstrate the renal arteries. We can also confirm 
that the right kidney is indeed higher than the left and that 
all images are from the same patient. 
We commend Dr Sandmann for his ability to repair 
similar thoracic dissections and fusiform aneurysms by open 
operation with minimal blood loss, expediency, and free- 
dom from the anxiety of paraplegia. Regrettably, this has not 
been our experience. 
Dr. Sandmann refers to the "pleasure" of performing 
open aortic replacement. We submit that the pleasure a
surgeon derives from an operation should not be a factor in 
the choice of the operation. Rather, the focus should be on 
the patient's welfare. Endoluminal aneurysm repair, as with 
other minimally invasive procedures, aims to correct the 
pathologic process with a minimum of discomfort and 
disruption of the patient's life. 
James May 
Geoffrey White 
Department ofSurgery 
Blackburn Bldg. D06 
University of Sydney 
Sydney, NSW 2006 
Australia 
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Regarding "Thrombolysis or peripheral arterial 
surgery: Phase I results" 
To the Editors: 
In the article "Thrombolysis or peripheral arterial 
surgery: Phase I results," Drs. Ouriel, Veith, and Sasahara, 
on behalf of the TOPAS Investigators (J Vasc Surg 1996; 
23:64-75), recommended that an initial recombinant 
urokinase dose of 4000 IU /min  would be safe and effica- 
cious (capable of producing the desired result) in the 
treatment of acute leg ischemia. Review of the article shows 
that all of the recommended doses were efficacious, but the 
authors believed that the 4000 IU /min  was most effica- 
cious. In making that decision, however, the surgeon must 
consider the cost of therapy, the cost of complications, and 
failed therapy. One method of evaluation is to consider the 
cost of standard urokinase in these treatment regimens. 
The cost of urokinase at our hospital is $344 per 
250,000 IU. Therefore, a 24-hour cost (average infusion 
time = 23 hours) of urokinase for the 2000 IU /min  regi- 
men is $3848, for the 4000 IU /min  regimen is $4489, and 
for the 6000 IU /min  regimen is $5,I30. 
Several assumptions must be made to evaluate the data 
from the article to give comparative costs. All groups were 
demographically similar and had definitive surgery. Group 
comparisons howed similar distribution of operations, 
making operative and hospitalization costs similar. If  one 
assumes that the complication of bleeding added 2 days to 
the hospitalization at a cost of $2000 per day, then each 
bleeding complication cost $4000. Therefore, the only 
variable in cost comparisons is the bleeding rate and the cost 
of that bleeding. This must be considered in the failure arm 
of any evaluation. 
This information can then be put into decision-tree 
analysis, with arms showing the cost of success and the cost 
of failure. Then, the most cost-efficient treatment can be 
selected. A decision tree for urokinase therapy is shown in 
Fig. 1. 
The cost ofurokinase therapy at an initial dose of 2000 
IU /min  totals $4368. The 4000 IU /min  regimen shows a 
cost of $4569, and the 6000 IU /min  dose a cost of $5770. 
Given the assumptions li ted above and the similar throm- 
bolysis effect (complete thrombolysis, 67% vs 71%), an 
initial urokinase dose of 2000 IU /min  is the most cost- 
efficient choice. Although the difference between the 2000 
IU /min  regimen and the 4000 IU /min  regimen is only 
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Fig. 1. Decision tree for urokinase therapy. 
$200 per patient, logic dictates that in time the bleeding 
complications should be less with a lesser dose ofurokinase. 
If that lessening occurs, then this cost analysis becomes even 
more practical. 
In future TOPAS articles, I would encourage the 
authors to include costs or charges, or even a decision 
analysis, so that we may all have more data to examine 
urokinase therapy in this age of cost containment. 
Dennis E. Weiland, MD 
Department of Surgery 
Maricopa Medical Center 
2610 E. Roosevelt 
Phoenix, AZ 85010 
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Reply 
To the Editors: 
Dr. Weiland has brought forth some interesting com- 
ments with regard to an economic analysis of the TOPAS 
phase I data. His principles are instructive in reiterating the 
necessity of a rational decision-tree analysis for cost-benefit 
assessment. Dr. Weiland's analysis, however, uses only 
bleeding complications a the measure with which to gauge 
success or failure of the procedure. Clearly, amputation and 
patient mortality rates overshadow bleeding as the most 
appropriate primary endpoints of success. 
The 4000 IU/min uroldnase dose was chosen by the 
investigators a the most appropriate dose to continue phase 
II after a review of all the primary and secondary endpoints 
available after a short period of follow-up. Economic 
outcome was not considered in this decision. Nevertheless, 
the lack of a difference in the length of hospital stay, 
concurrent with trends toward improved 1-year amputa- 
tion-free survival rates in the 4000 IU/min group 
(p = 0.07) suggests that the investigators made an appro- 
priate decision in choosing the intermediate dose. A formal 
cost-benefit analysis is now underway, and the investigators 
hope to have the opportunity to report his data in the near 
future. 
Kenneth Ouriel, MD 
Department of Surgery 
University of Rochester 
601 Elmwood Ave., Box SURG 
Rochester, NY 14642 
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